{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:13:58Z","timestamp":1790367238586,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.schres.2023.03.023","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T05:28:44Z","timestamp":1680240524000},"page":"195-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study"],"prefix":"10.1016","volume":"255","author":[{"given":"T.A.","family":"Tishler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.M.","family":"Ellingson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salvadore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Turkoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Subotnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"de la Fuente-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.H.","family":"Nuechterlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.03.023_bb0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2022.02.019","article-title":"The Disease Recovery Evaluation and Modification (DREaM) study: effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder","volume":"243","author":"Alphs","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.03.023_bb0010","series-title":"Practice Guidelines for the Treatment of Patients With Schizophrenia","year":"2020"},{"issue":"4","key":"10.1016\/j.schres.2023.03.023_bb0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/glia.21122","article-title":"GSK3beta negatively regulates oligodendrocyte differentiation and myelination in vivo","volume":"59","author":"Azim","year":"2011","journal-title":"Glia"},{"issue":"11","key":"10.1016\/j.schres.2023.03.023_bb0020","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1176\/ajp.147.11.1457","article-title":"Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia","volume":"147","author":"Barta","year":"1990","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.03.023_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0893-133X(02)00364-0","article-title":"Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation","volume":"27","author":"Bartzokis","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2023.03.023_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.schres.2011.06.029","article-title":"Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory","volume":"132","author":"Bartzokis","year":"2011","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2023.03.023_bb0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2012.06.036","article-title":"Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia","volume":"140","author":"Bartzokis","year":"2012","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.03.023_bb0040","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.schres.2009.06.014","article-title":"In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia","volume":"113","author":"Bartzokis","year":"2009","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2023.03.023_bb0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0006-3223(02)01835-8","article-title":"Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study","volume":"53","author":"Bartzokis","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.03.023_bb0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.schres.2023.03.023_bb0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2023.03.023_bb0060","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archpsyc.59.11.1002","article-title":"Brain volume changes in first-episode schizophrenia: a 1-year follow-up study","volume":"59","author":"Cahn","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2023.03.023_bb0065","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41386-021-00980-0","article-title":"Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: a longitudinal, randomised, triple-blind, placebo-controlled MRI Study","volume":"46","author":"Chopra","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.schres.2023.03.023_bb0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2006.09.009","article-title":"Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia","volume":"89","author":"Chua","year":"2007","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2023.03.023_bb0075","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/NMD.0000000000000286","article-title":"Brain imaging during the transition from psychosis prodrome to schizophrenia","volume":"203","author":"Chung","year":"2015","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2023.03.023_bb0080","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.schres.2020.03.073","article-title":"Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients","volume":"222","author":"Chwa","year":"2020","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2023.03.023_bb0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","article-title":"Medication adherence of individuals with a first episode of psychosis","volume":"106","author":"Coldham","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2023.03.023_bb0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0006-3223(91)90044-M","article-title":"Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study","volume":"29","author":"DeLisi","year":"1991","journal-title":"Biol. Psychiatry"},{"issue":"16","key":"10.1016\/j.schres.2023.03.023_bb0095","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1017\/S0033291717001313","article-title":"White matter connectivity disruptions in early and chronic schizophrenia","volume":"47","author":"Di Biase","year":"2017","journal-title":"Psychol. Med."},{"issue":"28","key":"10.1016\/j.schres.2023.03.023_bb0100","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1523\/JNEUROSCI.0150-08.2008","article-title":"Constitutively active Akt induces enhanced myelination in the CNS","volume":"28","author":"Flores","year":"2008","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.schres.2023.03.023_bb0105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archpsyc.60.6.585","article-title":"Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia","volume":"60","author":"Ho","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.03.023_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2023.03.023_bb0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","article-title":"The glamour and gloom of glycogen synthase kinase-3","volume":"29","author":"Jope","year":"2004","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.schres.2023.03.023_bb0120","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1017\/S0033291716000593","article-title":"Increased MRI-based cortical grey\/white-matter contrast in sensory and motor regions in schizophrenia and bipolar disorder","volume":"46","author":"Jorgensen","year":"2016","journal-title":"Psychol. Med."},{"issue":"5","key":"10.1016\/j.schres.2023.03.023_bb0125","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.IN18031AH1C","article-title":"Optimizing treatment choices to improve adherence and outcomes in schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2023.03.023_bb0130","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.03.023_bb0135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1176\/appi.ajp.160.1.156","article-title":"Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia","volume":"160","author":"Kasai","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.03.023_bb0140","article-title":"Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons","volume":"2012","author":"Kim","year":"2012","journal-title":"Schizophr. Res. Treat."},{"issue":"5","key":"10.1016\/j.schres.2023.03.023_bb0145","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","article-title":"Time course and biologic correlates of treatment response in first-episode schizophrenia","volume":"50","author":"Lieberman","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2023.03.023_bb0150","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","article-title":"The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches","volume":"50","author":"Lieberman","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2023.03.023_bb0155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/1471-244X-13-340","article-title":"Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness","volume":"13","author":"Llorca","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2023.03.023_bb0160","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1162\/0898929041920441","article-title":"Maturation of white matter is associated with the development of cognitive functions during childhood","volume":"16","author":"Nagy","year":"2004","journal-title":"J. Cogn. Neurosci."},{"issue":"21","key":"10.1016\/j.schres.2023.03.023_bb0165","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1523\/JNEUROSCI.0232-09.2009","article-title":"Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination","volume":"29","author":"Narayanan","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2023.03.023_bb0170","series-title":"Guide to Long-acting Medication for Providers And Organization","year":"2019"},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.03.023_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psychres.2004.04.018","article-title":"Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples","volume":"144","author":"Nuechterlein","year":"2006","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2023.03.023_bb0180","first-page":"1","article-title":"A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work\/school functioning","author":"Nuechterlein","year":"2020","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2023.03.023_bb0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.03.023_bb0190","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.161.3.473","article-title":"Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder","volume":"161","author":"Robinson","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.03.023_bb0195","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fnins.2015.00396","article-title":"Assessing intracortical myelin in the living human brain using myelinated cortical thickness","volume":"9","author":"Rowley","year":"2015","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.schres.2023.03.023_bb0200","doi-asserted-by":"crossref","first-page":"yw018","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind,noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2023.03.023_bb0205","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM199208273270905","article-title":"Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study","volume":"327","author":"Shenton","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.schres.2023.03.023_bb0210","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamapsychiatry.2020.0001","article-title":"Cognitive impairment in never-medicated individuals on the schizophrenia spectrum","volume":"77","author":"Sol\u00eds-Vivanco","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2023.03.023_bb0215","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuroimage.2018.10.023","article-title":"Depth-dependent intracortical myelin organization in the living human brain determined by in vivo ultra-high field magnetic resonance imaging","volume":"185","author":"Sprooten","year":"2019","journal-title":"NeuroImage"},{"issue":"8","key":"10.1016\/j.schres.2023.03.023_bb0220","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.03.023_bb0225","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/appi.ajp.2010.09010087","article-title":"Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia","volume":"168","author":"Subotnik","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2023.03.023_bb0230","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/mp.2008.34","article-title":"Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study","volume":"14","author":"Sun","year":"2009","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.03.023_bb0235","doi-asserted-by":"crossref","first-page":"339","DOI":"10.31887\/DCNS.2000.2.4\/ctamminga","article-title":"The biology of schizophrenia","volume":"2","author":"Tamminga","year":"2000","journal-title":"Dialogues Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2023.03.023_bb0240","first-page":"454","article-title":"Abnormal trajectory of intracortical myelination in schizophrenia implicates white matter in disease pathophysiology and the therapeutic mechanism of action of antipsychotics","volume":"3","author":"Tishler","year":"2018","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.schres.2023.03.023_bb0245","series-title":"2019\u20132020 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults","year":"2020"},{"issue":"3","key":"10.1016\/j.schres.2023.03.023_bb0250","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1034\/j.1600-0447.2000.102003203.x","article-title":"Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects","volume":"102","author":"Verdoux","year":"2000","journal-title":"Acta Psychiatr. Scand."}],"updated-by":[{"DOI":"10.1016\/j.schres.2025.05.023","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423001160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423001160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:43:42Z","timestamp":1763757822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":50,"alternative-id":["S0920996423001160"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.03.023","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}